Observes fruquintinib use in adults with advanced bowel cancer in Poland
Looks at how fruquintinib works in adults with spread colorectal cancer.
Plain-language title generated from the registry record
Registry title: A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Key facts
- Where
- Bialystok, Bydgoszcz, Gliwice, Krakow, Lublin, Opole, Poznan, Przemyśl, Szczecin, and Warsaw, PolandSee the 10 sites
Where in Poland
- Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku, Oddzial Onkologii Klinicznej im. dr E. Pileckiej z pododdzialem Chemioterapii DziennejBialystok, PolandTaking people
- Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, Ambulatorium ChemoterapiiBydgoszcz, PolandNot yet recruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy Oddzial w Gliwicach, Oddzial Chemioterapii DziennejGliwice, PolandNot yet recruiting
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny OnkologiiKrakow, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Klinika Chorob Metabolicznych i Immunoonkologii, Oddzial Onkologii KlinicznejLublin, PolandTaking people
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego w Opolu, Klinika Onkologii, Odcinek DziennyOpole, PolandNot yet recruiting
- Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej Curie, Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izb PrzyjecPoznan, PolandNot yet recruiting
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Oddzial Onkologiczny z Pod. Dziennej ChemioterapiiPrzemyśl, PolandTaking people
- Zachodniopomorskie Centrum Onkologii, Oddzial Onkologii KlinicznejSzczecin, PolandNot yet recruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Onkologii i RadioterapiiWarsaw, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT07623174
- Record updated
- 22 September 2026
- Original description
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life.Read full original descriptionShow less
FRAMEWORK-CRC: Fruquintinib Real-World Outcomes in mCRC - A Prospective Study of One-Year Progression-Free Survival and Overall Survival in Polish Patients
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life.
The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth.
Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study.
The study will look at data already existing in the participants' medical charts.
Inclusion: Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil; Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation; Participants for whom adequate medical records are available to support the data collection requirements.
Exclusion: Participant currently participates or plans to participate in an interventional clinical trial.